...
首页> 外文期刊>Cardiology Research >In-Hospital and Long-Term Outcomes of Beta-Blocker Treatment in Cocaine Users: A Systematic Review and Meta-analysis
【24h】

In-Hospital and Long-Term Outcomes of Beta-Blocker Treatment in Cocaine Users: A Systematic Review and Meta-analysis

机译:可卡因使用者的β-受体阻滞剂治疗的院内和长期结果:系统评价和荟萃分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Although β-blocker treatment is generally contraindicated in patients presenting with acute cocaine intoxication due to concern for unopposed α-receptor stimulation, some studies have reported that β-blocker treatment did not increase adverse events in these patients. As this treatment is still controversial, we performed a meta-analysis of observational studies on this topic. Methods: By searching three electronic databases (MEDLINE, EMBASE, and the Cochrane Library) from their inception to June 11, 2018, we identified eight observational studies with 2,048 patients who presented to hospital with cocaine-associated chest pain or after recent cocaine use. Outcomes of interest were myocardial necrosis or infarction (MI) and death during hospital stay or follow-up. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated by using a random-effects meta-analysis based on the DerSimonian-Laird method. Results: Among patients presenting with cocaine-associated chest pain or recent cocaine use, there was no significant difference in in-hospital all-cause mortality (RR, 0.59; 95% CI, 0.24 - 1.47) and MI (RR, 1.24; 95% CI, 0.74 - 2.06) between patients who did and did not receive β-blocker treatment during their hospital stay. During long-term follow-up (mean 2.6 years), there was no significant difference in all-cause mortality (RR, 0.79; 95% CI, 0.44 - 1.41) and MI (RR, 0.96; 95% CI, 0.40 - 2.33) between the two groups. Conclusions: These results suggest that β-blocker treatment in patients presenting with cocaine intoxication may not be as harmful as originally believed. Further clinical studies are needed to investigate this topic.
机译:背景:尽管由于担心α-受体刺激不受抑制,一般在患有急性可卡因中毒的患者中禁忌使用β-受体阻滞剂,但一些研究报告称,β-受体阻滞剂治疗并未增加这些患者的不良反应。由于这种治疗方法仍存在争议,因此我们对该主题的观察性研究进行了荟萃分析。方法:通过搜索三个电子数据库(MEDLINE,EMBASE和Cochrane库),从他们的成立到2018年6月11日,我们确定了8项观察性研究,涉及2,048例因可卡因相关的胸痛或最近使用可卡因入院的患者。感兴趣的结果是住院或随访期间的心肌坏死或梗死(MI)和死亡。使用基于DerSimonian-Laird方法的随机效应荟萃分析,计算了具有95%置信区间(CI)的合并相对风险(RR)。结果:在出现可卡因相关性胸痛或近期使用可卡因的患者中,院内全因死亡率(RR,0.59; 95%CI,0.24-1.47)和MI(RR,1.24; 95)无显着差异在住院期间接受和未接受β受体阻滞剂治疗的患者之间的%CI,0.74-2.06)。在长期随访(平均2.6年)中,全因死亡率(RR,0.79; 95%CI,0.44-1.41)和MI(RR,0.96; 95%CI,0.40-2.33)没有显着差异。 )。结论:这些结果表明,对可卡因中毒患者进行β受体阻滞剂治疗可能没有最初认为的那样有害。需要进一步的临床研究来研究这个话题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号